Join us for a deep-dive conversation with Dr Emil Kendziorra, CEO of Tomorrow.bio, as we explore the cutting edge of cryopreservation and medical biostasis.
Dr Kendziorra, who began his career in cancer research with a summa cum laude degree from the University of Göttingen, shares his remarkable journey from academic science to entrepreneurship, and ultimately to founding Tomorrow.bio — a company he considers his life’s work.
In this interview, he discusses the motivations behind his pivot from traditional longevity research to the frontier of cryomedicine, the operational and emotional lessons learned from cryopreserving over 20 human patients and 10 pets, and his vision for making this technology more accessible in the future.
Tomorrow.bio stands as Europe’s fastest-growing cryopreservation company, with over 800 members across 200+ cities and 45+ countries. The company offers both whole-body cryopreservation and brain-only preservation, using a transparent pricing model designed for long-term value.
With a recent €5 million Seed round and a mission to advance medical biostasis, Emil discusses the unique challenges and opportunities of operating in this space, the ethical considerations of a technology that may not achieve revival for decades, and his long-term vision for the field.
Key Points.
